Michael Smith - Insmed Sr Counsel
| INSM Stock | USD 73.15 0.66 0.89% |
Insider
Michael Smith is Sr Counsel of Insmed Inc
| Age | 46 |
| Address | 700 US Highway 202/206, Bridgewater, NJ, United States, 08807 |
| Phone | 908 977 9900 |
| Web | https://www.insmed.com |
Michael Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Smith against Insmed stock is an integral part of due diligence when investing in Insmed. Michael Smith insider activity provides valuable insight into whether Insmed is net buyers or sellers over its current business cycle. Note, Insmed insiders must abide by specific rules, including filing SEC forms every time they buy or sell Insmed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Smith over a month ago Disposition of 11900 shares by Michael Smith of Insmed at 17.16 subject to Rule 16b-3 | ||
Michael Smith over a month ago Disposition of 834 shares by Michael Smith of ICC Holdings subject to Rule 16b-3 | ||
Michael Smith over a month ago Disposition of 730 shares by Michael Smith of Insmed at 70.05 subject to Rule 16b-3 | ||
Michael Smith over a month ago Disposition of 3121 shares by Michael Smith of Doma Holdings at 0.282 subject to Rule 16b-3 |
Insmed Management Efficiency
The company has return on total asset (ROA) of (0.2605) % which means that it has lost $0.2605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Debt To Assets is likely to grow to 0.91, though Net Tangible Assets are likely to grow to (127.7 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| David Pompliano | Revolution Medicines | N/A | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Byron JD | Janux Therapeutics | 59 | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| David Bradshaw | Harmony Biosciences Holdings | N/A | |
| Timothy Rolph | Akero Therapeutics | 70 | |
| Brian MBA | Agios Pharm | 55 | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| Jeffrey Aronin | Harmony Biosciences Holdings | 56 | |
| Kevin Mannix | BeiGene | N/A | |
| Michael Flanagan | Avidity Biosciences | 62 | |
| Prof Davis | Avidity Biosciences | N/A | |
| Dr DACVP | Agios Pharm | 63 | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Daniel Maller | BeiGene | N/A | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Kathleen Gallagher | Avidity Biosciences | N/A | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.26 |
Insmed Inc Leadership Team
Elected by the shareholders, the Insmed's board of directors comprises two types of representatives: Insmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insmed. The board's role is to monitor Insmed's management team and ensure that shareholders' interests are well served. Insmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mandy Fahey, Executive Communications | ||
| Sara MBA, Chief Officer | ||
| Nicole MBA, Chief Officer | ||
| John Wise, Head VP | ||
| MBA JD, CEO President | ||
| Eleanor Barisser, Associate Relations | ||
| MD MBA, Chief Officer | ||
| Roger Adsett, Chief Commercial Officer | ||
| John III, VP Officer | ||
| John MBA, Chief Officer | ||
| Nicole Schaeffer, Sr. VP of HR and Corporate Services | ||
| Michael Smith, Sr Counsel | ||
| Michael JD, Chief Secretary | ||
| Roger MBA, Chief Officer | ||
| Brian Kaspar, Chief Officer | ||
| MD FCCP, Chief Officer |
Insmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.52) % | ||||
| Operating Margin | (2.13) % | ||||
| Current Valuation | 12.53 B | ||||
| Shares Outstanding | 178.9 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 99.09 % | ||||
| Number Of Shares Shorted | 13.85 M | ||||
| Price To Earning | (8.70) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.